Enliven Therapeutics director Mika Derynck sells $9.56m shares
What it means
- What to watch: There is a hard number in this story ($9) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $ELVN -5.21% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$ELVN last traded at $44.79, -5.21% on the session. That puts it 28% shy of its 52-week high of $62.32 and 203% clear of its low of $14.79 — a little above the middle of the range. Over the year it has ranged 322% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ELVN page.
How much coverage it is getting
Nothing else on $ELVN in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$ELVN earnings in 5 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $ELVN page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. And Wook AI, up top, will happily do the math — how far $ELVN sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ELVN. It carried $9.56 million and 9.56 shares, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 7, 2026. $ELVN has moved -25.92% ($60.46 to $44.79). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.